A project to find new biomarkers in kidney disease

PRIME-CKD Project (Personalized response to medication: implementation and evaluation in chronic kidney disease), which was launched in January and will run for five years, will demonstrate in the clinical setting the usefulness of new biomarkers as tools to improve the selection of drug therapies for patients with kidney disease, for use in daily clinical practice. and in innovative clinical trials.

PRIME-CKD has brought together a large group of professionals with expertise in cardiovascular medicine and especially in chronic kidney disease to address key challenges that allow for the improvement of current therapies and the application of personalized medicine for the day-to-day management of this disease.

Specifically, for the first time in a chronic disease context, the evaluation of biomarkers that link the pathophysiology of an individual disease to a drug’s mechanism of action will be sought – through the European Medicines Agency and the US Food and Drug Administration (FDA) – to advance personalized medicine, which will allow for adaptive therapies. With different responses for each patient.

The best treatment at the right time

“The results of this project are expected to translate into significant benefits for patients and reduce social costs associated with chronic kidney disease, by ensuring that patients receive the most effective treatment in a timely manner to slow or prevent kidney failure requiring dialysis or organ transplantation,” says the program coordinator. Hiddo JL Heerspink, University Medical Center Groningen, The Netherlands.

Participating in this project is the INCLIVA Health Research Institute’s Nephrology Research Team led by Dr. José Luis Jurez. His intervention is based on researching and analyzing biomarkers of patients with chronic kidney disease from the Department of Health of Valencia Clinico Malvarrosa in different phases of the project. The findings will help reveal biomarkers of progression of kidney disease and different response to treatment and advanced personalized medicine adjusted to the characteristics and response of each patient.

Dr. Gorez expressed his satisfaction “to participate in the PRIME-CKD program, which is built on the solid foundation of kidney research and the vision of precision medicine that has been developed in Europe in recent years.” “Without a doubt, it could be a huge step in preventing the progression of chronic kidney disease. There is still a lot to learn, especially regarding each patient’s individual response to current therapies. It is the future of kidney disease and cardiovascular medicine,” he added.

Participants

The PRIME-CKD Consortium will translate the new findings into clinical practice by bringing together a group of experts to develop evidence-based tools and a roadmap for unlocking the potential of precision medicine in the treatment of chronic kidney disease.

PRIME-CKD is funded by Horizon Europe, the European Union’s Horizon Europe research and innovation framework programme. The total budget of the project is 9.9 million euros for a period of 5 years. In addition to INCLIVA, 14 other entities are involved: the University Medical Center Hamburg-Eppendorf and the University Hospital Erlangen (Germany); Hovedstaden district (Denmark); Renalytix AI Limited (Ireland); University of Campania Luigi Vanvitelli, Alma mater Studiorum – University of Bologna and Irccs Azienda Ospedaliero-Universitaria of Bologna (Italy); Hessels en Grob BV, Drug Evaluation Board, Dutch Kidney Foundation and Academic Hospital Groningen, The Netherlands; Lund University (Sweden); University of Leicester and University Hospitals of Leicester NHS Trust (UK), University of Michigan, University of Michigan Governors (USA).